Overview
- Senator Maggie Hassan has asked GSK and Prasco Laboratories to submit internal documents by July 18 as part of a Senate Finance Committee probe into the January 2024 discontinuation of Flovent HFA
- GSK pulled its brand-name pediatric inhaler to replace it with a higher-priced authorized generic through Prasco Laboratories, a tactic to avoid higher Medicaid rebates
- A Johns Hopkins analysis found the company saved $367 million in Medicaid rebates in 2024 while the program spent over $550 million on the generic
- A published study reported a 17.5% increase in childhood asthma hospitalizations in the three months following the inhaler’s market removal
- Parents say they have paid up to $150 per authorized generic inhaler instead of $10 for Flovent HFA, and although GSK plans a $35 monthly cost cap from January 2025, coverage and device compatibility issues remain